DNA Software is building better diagnostics with its partners to deliver SARS-CoV-2 (COVID-19), FluA and FluB multiplexed PCR assays.

DNA Software is uniquely capable of delivering multiplex assay designs, leveraging the advantage of our multi-state coupled equilibrium models and prediction of off-target hybridization with ThermoBLAST. DNA Software has been recently recognized “best in class” for highly specific and sensitive multiplex design.

  • Multiplex PCR assays which can detect SARS-CoV-2, with two targets (i.e. ORF8 and N genes) along with influenza A virus (multiple segments), and influenza B virus with an RNase P control.
  • Multiplex design which will differentiate FluA from FluB ( detecting A(H1).
  • A(H1)pdm09, A(H3).
  • DNA Software has delivered multiplex designs to its partners which are in clinical validation for CLIA use and seeking FDA approval.
  • Multiplex can also include RSV detection.
  • Consensus designs (covering all variants) of SARS-CoV-2, FluA, FluB, and RSV from manually curated DNA Software databases

Why can PanelPlex™-Consensus help build uniquely sensitive and specific PCR assays to detect SARS-CoV-2, Flu A, & Flu B including all variants?

  1. Rigorously validated for the detection of thousands of bacteria, viruses and human targets.
  2. Provides consensus designs PCR assays to detect all sequence variants of a given virus. Often, this is accomplished with a single primer pair (i.e. singleplex reaction) while in other cases with high sequence diversity a small multiplex reaction is required (typically 1 to 5 plex is required).  For example, we have made singleplex assays for pandemic 2009 H1N1 FluA, and 7-plex assay for the highly divergent Lassa virus.
  3. Allows the user to input panels of GenBank accessions to form inclusivity, exclusivity (i.e. phylogenetically near neighbor sequences), and background lists.
  4. Saves over six months on average of iterative experimental trial-and-error optimization.
  5. Uses our proprietary ThermoBLAST and TargAn (target analysis) algorithms so that the assays are designed with maximum coverage of sequence variants with minimum false positives and false negatives.
  6. Fully capable of designing a new assay to address the (COVID-19) Coronavirus.
  PanelPlexTM-Consensus Traditional Design
First pass of multiplex primer design 80-90% >50% *
Second pass of multiplex primer design 98-99% <70%
Time to functional design <2 days >6 months

* Based on personal communication with PCR specialist at Roche and Sr. Scientist at a Boston based Biotech company


Contact Us

Dna Software provides its customers direct access to its software solutions as well as performing custom assay designs on a contact basis.
Panelplex-Consensus as been recognized as in 2019 by Frost and Sullivan as best in class in the industry.